NCT07179900View on ClinicalTrials.gov

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

QL1706

Apololitovoreli monoclonal antibody (QL1706) 7.5mg/kg intravenous infusion, once every 3 weeks

RADIATION

Radiotherapy

41.4-50.4Gy/1.8Gy/23-28F

DRUG

Sintilimab

200mg q3w

DRUG

Bevacizumab

15mg/kg q3w

All Listed Sponsors
lead

Hebei Medical University Fourth Hospital

OTHER